A Study for the PanCystPro Assay in the Management of Pancreatic Cystic Lesions
NCT ID: NCT06894329
Last Updated: 2025-09-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
50 participants
OBSERVATIONAL
2025-12-15
2027-03-16
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Cyst Fluid Glucose for On-site Diagnosis of Mucinous Pancreatic Cysts
NCT03169842
Accuracy of Dilution of EUS-FNA Pancreatic Cyst Fluid for Carcinoembryonic Antigen (CEA) Measurement
NCT01494077
Confirmation of Association Between Cystic Fluid Analysis With Pancreatic Cystic Lesions
NCT05497271
A Prospective Study To Identify Predictive Biological Markers In Blood And Cyst Fluid Aspirates From Patients With Pancreatic Cyst Lesions
NCT02647177
Pancreatic Cyst Ablation With a Monopolar Radiofrequency Ablation Probe
NCT04253249
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The impact of PanCystPro on clinical management intention will be assessed after the PanCystPro result has been received by the physician. One year after enrollment the actual clinical management the patient received will be assessed.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Cross sectional imaging studies demonstrating a pancreatic cyst at least 12 mm in size where fluid sampling can aid in patient's management
* Written informed consent.
* The patient will be undergoing EUS with anticipated FNA extraction as part of standard patient care.
Exclusion Criteria
* Pregnant or lactating females.
* Patients with contraindications to moderate or deep procedural sedation (necessary for the conduct of the endoscopic ultrasound) like major cardiorespiratory illness.
* Patients with contraindications to FNA of a pancreatic cyst like being on blood thinners.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Amplified Sciences Inc
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PanAMP study
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.